<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271412</url>
  </required_header>
  <id_info>
    <org_study_id>LY03005 MAD</org_study_id>
    <secondary_id>LY03005/CT-USA-102</secondary_id>
    <nct_id>NCT02271412</nct_id>
  </id_info>
  <brief_title>Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luye Pharma Group Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luye Pharma Group Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objectives&#xD;
&#xD;
        -  To evaluate the safety and tolerability of escalating multiple oral doses of LY03005 in&#xD;
           healthy subjects.&#xD;
&#xD;
        -  To characterize the pharmacokinetics of escalating multiple oral doses of LY03005.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a randomized, double-blind, placebo-controlled, multiple ascending dose study to&#xD;
      be conducted in the US. Approximately 48 healthy subjects will be enrolled into one of the&#xD;
      four groups&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>3 to 4 months</time_frame>
    <description>Safety and Tolerability of LY03005</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Major Depressive Disorder, Recurrent, Unspecified</condition>
  <arm_group>
    <arm_group_label>LY03005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY03005 40, 80, 120, or 160 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at 40, 80, 120, or 160 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY03005</intervention_name>
    <description>LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.</description>
    <arm_group_label>LY03005</arm_group_label>
    <other_name>4-Methylbenzoate of desvenlafaxine hydrochloride</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Are capable of giving informed consent and complying with study procedures;&#xD;
&#xD;
          2. Are between the ages of 18 and 45 years, inclusive;&#xD;
&#xD;
          3. A negative pregnancy test result prior to screening and admission for all female&#xD;
             subjects, and meet the following criteria defined as:&#xD;
&#xD;
               1. If child-bearing potential, agree to avoid pregnancy during the study and one&#xD;
                  month after the end of the study by using effective contraceptive method(s), such&#xD;
                  as an intrauterine device (IUD), diaphragm with spermicide, and condoms with&#xD;
                  spermicide.&#xD;
&#xD;
               2. Surgically sterile for at least 3 months prior to screening&#xD;
&#xD;
               3. Postmenopausal&#xD;
&#xD;
          4. Considered healthy by the Principal Investigator, based on a detailed medical history,&#xD;
             full physical examination, clinical laboratory tests, 12-lead ECG and vital signs;&#xD;
&#xD;
          5. Nonsmoker, defined as not having smoked or used any form of tobacco in more than 6&#xD;
             months before screening;&#xD;
&#xD;
          6. Body mass index (BMI) of 19 to 30 kg/m2 inclusive and body weight not less than 50 kg;&#xD;
&#xD;
          7. Willing and able to adhere to study restrictions and to be confined at the clinical&#xD;
             research center.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects will be excluded from study entry if any of the following exclusion criteria are&#xD;
        present at screening or admission:&#xD;
&#xD;
          1. Clinically significant history of gastrointestinal, cardiovascular, musculoskeletal,&#xD;
             endocrine, hematologic, psychiatric, renal, hepatic, bronchopulmonary, neurologic,&#xD;
             immunologic, lipid metabolism disorders, or drug hypersensitivity;&#xD;
&#xD;
          2. Subjects with a mean systolic blood pressure of three measurements less than 130 mmHG,&#xD;
             or a mean diastolic blood pressure of three measurements less than 90 mmHG at&#xD;
             screening. Blood pressure will be measured at supine position.&#xD;
&#xD;
          3. Known or suspected malignancy;&#xD;
&#xD;
          4. Positive blood screen for human immunodeficiency virus (HIV), or hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis C virus;&#xD;
&#xD;
          5. A history of seizure. However, a history of febrile seizure is allowed;&#xD;
&#xD;
          6. Positive pregnancy test result, or plan to become pregnant if female;&#xD;
&#xD;
          7. A hospital admission or major surgery within 30 days prior to screening;&#xD;
&#xD;
          8. Participation in any other investigational drug trial within 30 days prior to&#xD;
             screening;&#xD;
&#xD;
          9. DSM-V substance use disorder within 6 months prior to screening;&#xD;
&#xD;
         10. A positive result for alcohol or drugs of abuse at screening or admission;&#xD;
&#xD;
         11. Tobacco use within 6 months prior to screening;&#xD;
&#xD;
         12. An unwillingness or inability to comply with food and beverage restrictions during&#xD;
             study participation;&#xD;
&#xD;
         13. Donation or blood collection of more than 1 unit (approximate 450 mL) of blood (or&#xD;
             blood products) or acute loss of blood during the 90 days prior to screening;&#xD;
&#xD;
         14. Use of prescription or over-the-counter (OTC) medications, and herbal medicines&#xD;
             (including St John's Wort, herbal teas, garlic extracts)within 14 days prior to dosing&#xD;
             (Note: Use of acetaminophen at &lt; 3g/day is permitted until 24 hours prior to dosing);&#xD;
&#xD;
         15. A history of intolerance or hypersensitivity to venlafaxine or desvenlafaxine or any&#xD;
             excipients;&#xD;
&#xD;
         16. A history of suicide attempt in the past 12 months and/or seen by the investigator as&#xD;
             having a significant history of risk of suicide or homicide; 17 An unwillingness of&#xD;
             male participants to use appropriate contraceptive measures if engaging in sex&#xD;
             intercourse with a female partner of childbearing potential. Appropriate measures&#xD;
             include use of a condom and spermicide and, for female partners, use of an&#xD;
             intrauterine device (IUD), diaphragm with spermicide, oral contraceptives, injectable&#xD;
             progesterone, progesterone sub-dermal implants, or a tubal ligation. Sexual&#xD;
             intercourse with pregnant or lactating women is prohibited.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Krefetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>PRA - CRI Lifetree</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>PRA Health Sciences</name>
      <address>
        <city>Marlton</city>
        <state>New Jersey</state>
        <zip>08053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <study_first_submitted>October 20, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>October 20, 2015</last_update_submitted>
  <last_update_submitted_qc>October 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

